Cited by 1,752Phagocytosis and Immune RegulationAcute Myeloid Leukemia ResearchFlavonoids in Medical Research

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Open access

Majeti, Ravindra, Chao, Mark P., Alizadeh, Ash A., Pang, Wendy W., Jaiswal, Siddhartha, Gibbs, Kenneth D., van Rooijen, Nico, Weissman, Irving L.·2009·Cell

DOI 10.1016/j.cell.2009.05.045PMC PMC2726837

Open this paper in CoChat — free account

Abstract

Acute myeloid leukemia (AML) is organized as a cellular hierarchy initiated and maintained by a subset of self-renewing leukemia stem cells (LSC). We hypothesized that increased CD47 expression on human AML LSC contributes to pathogenesis by inhibiting their phagocytosis through the interaction of CD47 with an inhibitory receptor on phagocytes. We found that CD47 was more highly expressed on AML LSC than their normal counterparts, and that increased CD47 expression predicted worse overall survival in three independent cohorts of adult AML patients. Furthermore, blocking monoclonal antibodies directed against CD47 preferentially enabled phagocytosis of AML LSC and inhibited their engraftment in vivo. Finally, treatment of human AML LSC-engrafted mice with anti-CD47 antibody depleted AML and targeted AML LSC. In summary, increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2009.05.045

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Self-citation
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
Grimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P., Zheleznyak, A., Fang, Y., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,975
Cancer Stem Cells
Jordan, C. T., Guzmán, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,748
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Self-citation
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 2×
“Consistent with this hypothesis, we have shown that pre-leukemic mutations occur in a clonal HSC population, eventually leading to the development of LSC at the MPP stage in AML or the granulocyte-macrophage progenitor (GMP) stage in myeloid blast crisis chronic myeloid leukemia (CML) (Jamieson et al., 2004; Miyamoto…”
BackgroundSelf-citation
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452

Flagged first, then by citations

Show all 47 references

1 of the 47 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 1,001

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 166
Humanized hemato-lymphoid system mice
Theocharides, A. P. A., Rongvaux, A., Fritsch, K., Flavell, R. A., & Manz, M. G. (2015) · Haematologica · doi:10.3324/haematol.2014.115212 · Cited by 174
Immune targets in the tumor microenvironment treated by radiotherapy
Ozpiskin, O. M., Zhang, L., & Li, J. J. (2019) · Theranostics · doi:10.7150/thno.32648 · Cited by 163
The cGAS-STING Pathway: A Promising Immunotherapy Target
Ou, L., Zhang, A., Cheng, Y., & Chen, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795048 · Cited by 166
Role of CD47 in Hematological Malignancies
Eladl, E., Tremblay‐LeMay, R., Rastgoo, N., Musani, R., Chen, W.-M., Liu, A., & Chang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00930-1 · Cited by 163
Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer
Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
Majeti, R. (2010) · Oncogene · doi:10.1038/onc.2010.511 · Cited by 164
Self-citation
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice
Han, M. H., Lundgren, D. H., Jaiswal, S., Chao, M., Graham, K. L., Garris, C. S., Axtell, R. C., Ho, P. P., Lock, C. B., Woodard, J. I., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20101974 · Cited by 157
Self-citation
Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis
Hu, T., Liu, H., Liang, Z., Wang, F., Zhou, C., Zheng, X., Zhang, Y., Song, Y., Hu, J., He, X., et al. (2020) · Theranostics · doi:10.7150/thno.40860 · Cited by 160
Programmed cell removal by calreticulin in tissue homeostasis and cancer
Feng, M., Marjon, K. D., Zhu, F., Weissman-Tsukamoto, R., Levett, A., Sullivan, K., Kao, K. S., Markovic, M., Bump, P. A., Jackson, H. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05211-7 · Cited by 159
Self-citation
Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy
Saeed, M., Gao, J. X., Shi, Y., Lammers, T., & Yu, H. (2019) · Theranostics · doi:10.7150/thno.37568 · Cited by 155
CD99 is a therapeutic target on disease stem cells in myeloid malignancies
Chung, S. S., Eng, W. S., Hu, W., Khalaj, M., Garrett-Bakelman, F. E., Tavakkoli, M., Levine, R. L., Carroll, M. P., Klimek, V. M., Melnick, A. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2025 · Cited by 156
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity
Cui, L., Chen, S.-Y., Lerbs, T., Lee, J.-W., Domizi, P., Gordon, S., Kim, Y.-H., Nolan, G., Betancur, P., & Wernig, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16466-4 · Cited by 153
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer
Zhao, H., Wang, J., Kong, X., Li, E., Liu, Y., Du, X., Kang, Z., Tang, Y. C., Kuang, Y., Yang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep29719 · Cited by 152
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
Wisnovsky, S., Möckl, L., Malaker, S. A., Pedram, K., Hess, G. T., Riley, N. M., Gray, M. A., Smith, B. A. H., Bassik, M. C., Moerner, W. E., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015024118 · Cited by 152
CD47–SIRPα-targeted therapeutics: status and prospects
Maute, R. L., Xu, J., & Weissman, I. L. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100070 · Cited by 159
Self-citation
The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses
Pachynski, R. K., Zabel, B. A., Kohrt, H. E. K., Tejeda, N., Monnier, J., Swanson, C., Holzer, A. K., Gentles, A. J., Sperinde, G. V., Edalati, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112124 · Cited by 159
Self-citation
Harnessing anti‐tumor and tumor‐tropism functions of macrophages via nanotechnology for tumor immunotherapy
Zheng, Y., Han, Y., Sun, Q., & Li, Z. (2022) · Exploration · doi:10.1002/exp.20210166 · Cited by 151
Fusobacterium nucleatum and its associated systemic diseases: epidemiologic studies and possible mechanisms
Fan, Z., Tang, P., Li, C., Yang, Q., Xu, Y., Su, C., & Li, L. (2023) · Journal of Oral Microbiology · doi:10.1080/20002297.2022.2145729 · Cited by 150
Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome
Koelzer, V. H., Canonica, K., Dawson, H., Sokol, L., Karamitopoulou, E., Lugli, A., & Zlobec, I. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1106677 · Cited by 149
CD47/SIRPα axis: bridging innate and adaptive immunity
van Duijn, A. V. D. P. , van der Burg, S. H., & Scheeren, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004589 · Cited by 151
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Piccione, E. C., Juárez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., & Majeti, R. (2015) · mAbs · doi:10.1080/19420862.2015.1062192 · Cited by 148
Self-citation
Overview of Cancer Stem Cells and Stemness for Community Oncologists
Lathia, J. D., & Liu, H. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0508-3 · Cited by 154
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 146
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies
Raggi, C., Mousa, H. S., Correnti, M., Sica, A., & Invernizzi, P. (2015) · Oncogene · doi:10.1038/onc.2015.132 · Cited by 148
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Zhou, X., Liu, X., & Huang, L. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202006220 · Cited by 147
Recent advances in acute myeloid leukemia stem cell biology
Horton, S. J., & Huntly, B. J. P. (2012) · Haematologica · doi:10.3324/haematol.2011.054734 · Cited by 149
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Zhao, A., Zhou, H., Yang, J., Li, M., & Niu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01342-6 · Cited by 153
Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates
Milani, M., Annoni, A., Moalli, F., Liu, T., Cesana, D., Calabria, A., Bartolaccini, S., Biffi, M., Russo, F., Visigalli, I., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7325 · Cited by 148
Engineered CD47 protects T cells for enhanced antitumour immunity
Yamada‐Hunter, S. A., Theruvath, J. L., McIntosh, B. J., Freitas, K. A., Lin, F. H. S., Radosevich, M., Leruste, A., Dhingra, S., Martínez-Vélez, N., Xu, P., et al. (2024) · Nature · doi:10.1038/s41586-024-07443-8 · Cited by 147
Self-citation
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Daver, N. G., Vyas, P., Kambhampati, S., Malki, M. M. A., Larson, R. A., Asch, A. S., Mannis, G. N., Chai‐Ho, W., Tanaka, T. N., Bradley, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02604 · Cited by 141
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 146
Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis
Corces, M. R., & Majeti, R. (2014) · Leukemia · doi:10.1038/leu.2014.211 · Cited by 147
Self-citation
Cancer Immunotherapy: Accomplishments to Date and Future Promise
Helmy, K. Y., Patel, S. A., Nahas, G. R., & Rameshwar, P. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.88 · Cited by 146
Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells
Bian, Z., Shi, L., Guo, Y.-L., Lv, Z., Tang, C., Niu, S., Tremblay, A., Venkataramani, M., Culpepper, C. D., Li, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521069113 · Cited by 140
Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors
Kaur, S., Soto‐Pantoja, D. R., Stein, E. V., Liu, C., ELKAHLOUN, A. G., Pendrak, M. L., Nicolae, A., SINGH, S. P., Nie, Z., Levens, D., et al. (2013) · Scientific Reports · doi:10.1038/srep01673 · Cited by 141
Localized CD47 blockade enhances immunotherapy for murine melanoma
Ingram, J. R., Blomberg, O. S., Sockolosky, J. T., Ali, L. R., Schmidt, F. I., Pishesha, N., Espinosa, C. A., Dougan, S. K., García, K. C., Ploegh, H. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710776114 · Cited by 139
Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 140
Technology Roadmap of Micro/Nanorobots
Ju, X., Chen, C., Oral, Ç. M., Sevim, S., Golestanian, R., Sun, M., Bouzari, N., Lin, X., Urso, M., Nam, J. S., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c03911 · Cited by 143
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
Chanier, T., & Chames, P. (2019) · Antibodies · doi:10.3390/antib8010013 · Cited by 140
Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts
Theocharides, A. P. A., Jin, L., Cheng, P.-Y., Prasolava, T. K., Malko, A. V., Ho, J., Poeppl, A. G., van Rooijen, N., Minden, M. D., Danska, J. S., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120502 · Cited by 139
Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics
Velten, L., Story, B. A., Hernández-Malmierca, P., Raffel, S., Leonce, D. R., Milbank, J. H., Paulsen, M. S., Demir, A., Szu‐Tu, C., Frömel, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21650-1 · Cited by 144
Tumor Dormancy and Cancer Stem Cells: Two Sides of the Same Coin?
Kleffel, S., & Schatton, T. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-1445-2_8 · Cited by 140
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies
Gebremeskel, S., & Johnston, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6113 · Cited by 139
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
Zeijlemaker, W., Kelder, A., Oussoren-Brockhoff, Y. J. M., Scholten, W. J., Snel, A. N., Veldhuizen, D., Cloos, J. J., Ossenkoppele, G. J., & Schuurhuis, G. J. (2015) · Leukemia · doi:10.1038/leu.2015.252 · Cited by 134
A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Kügler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., Schubert, I. A., Singer, H., Oduncu, F. S., Stockmeyer, B., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08300.x · Cited by 135
Cancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer
Jin, F., Qi, J., Liu, D., You, Y., Shu, G., Du, Y., Wang, J., Xu, X., Ying, X., Ji, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.021 · Cited by 132
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation
Garg, A. D., Romano, E., Rufo, N., & Agostinis, P. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.5 · Cited by 133
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
He, S., Busfield, S. J., Ritchie, D. S., Hertzberg, M., Durrant, S., Lewis, I. D., Marlton, P. V., McLachlan, A. J., Kerridge, I., Bradstock, K. F., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.956316 · Cited by 130
Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy
Wu, M., Le, W., Mei, T., Wang, Y., Chen, B., Liu, Z., & Xue, C. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200284 · Cited by 130
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
Upton, R., Banuelos, A. M., Feng, D., Biswas, T., Kao, K. S., McKenna, K. M., Willingham, S. B., Ho, P. Y., Rosental, B., Tal, M. C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026849118 · Cited by 134
Self-citation
Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia
Wémeau, M., Kepp, O., Tesnière, A., Panaretakis, T., Flament, C., de Botton, S., Zitvogel, L., Kroemer, G., & Chaput, N. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.82 · Cited by 134
Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development
Montico, B., Nigro, A., Casolaro, V., & Col, J. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020594 · Cited by 133
The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target
Takimoto, C. H. M., Chao, M. P., Gibbs, C., Mccamish, M. A., Liu, J., Chen, J. Y., Majeti, R., & Weissman, I. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz006 · Cited by 128
Self-citation
The landscape overview of CD47-based immunotherapy for hematological malignancies
Yang, H., Xun, Y., & You, H. (2023) · Biomarker Research · doi:10.1186/s40364-023-00456-x · Cited by 128
Xenograft models for normal and malignant stem cells
Goyama, S., Wunderlich, M., & Mulloy, J. C. (2015) · Blood · doi:10.1182/blood-2014-11-570218 · Cited by 127
Complexity of cancer stem cells
Sugihara, E., & Saya, H. (2013) · International Journal of Cancer · doi:10.1002/ijc.27961 · Cited by 132
Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
Nicholas, N. S., Apollonio, B., & Ramsay, A. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.003 · Cited by 131
Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer
Alhosin, M., Omran, Z., Zamzami, M. A., Al-Malki, A. L., Choudhry, H., Mousli, M., & Bronner, C. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0453-5 · Cited by 126
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
Wang, H., Sun, Y., Zhou, X., Chen, C., Jiao, L., Li, W., Gou, S., Li, Y., Du, J., Chen, G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000905 · Cited by 123
Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications
Liao, Y., Zhang, Y., Blum, N. T., Lin, J., & Huang, P. (2020) · Nanoscale Horizons · doi:10.1039/d0nh00267d · Cited by 122
Targeting tumor-associated macrophages for cancer immunotherapy
Shu, Y., & Cheng, P. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188434 · Cited by 122
Clonal evolution of acute leukemia genomes
Jan, M., & Majeti, R. (2012) · Oncogene · doi:10.1038/onc.2012.48 · Cited by 129
Self-citation
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L. M., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 124
Antibody and antibody fragments for cancer immunotherapy
Chen, W., Yang, Y., & Jiang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.021 · Cited by 123
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia
岩崎, 正., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.008 · Cited by 123
Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium
Vallabhapurapu, S., Blanco, V., Sulaiman, M. K., Vallabhapurapu, S. L., Chu, Z., Franco, R. S., & Qi, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6045 · Cited by 119
Regulation of CD47 expression in cancer cells
Huang, C.-Y., Ye, Z.-H., Huang, M., & Lu, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100862 · Cited by 128
Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy
Meng, Q., Zhao, Y., Dong, C., Liu, L., Pan, Y., Lai, J., Liu, Z., Yu, G., Chen, X. S., & Rao, L. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202108342 · Cited by 120
CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer
Yoshida, K., Tsujimoto, H., Matsumura, K., Kinoshita, M., Takahata, R., Matsumoto, Y., Hiraki, S., Ono, S., Seki, S., Yamamoto, J., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.478 · Cited by 118
Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials
Pollyea, D. A., Gutman, J. A., Gore, L., Smith, C. A., & Jordan, C. T. (2014) · Haematologica · doi:10.3324/haematol.2013.085209 · Cited by 122
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3
Ahmed, M., Cheng, M. H., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H.-F., Larson, S. M., & Cheung, N. V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679852 · Cited by 117
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
Pietsch, E. C., Dong, J., Cardoso, R., Zhang, X., Chin, D., Hawkins, R., Dinh, T., Zhou, M., Strake, B., Feng, P.-H., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.7 · Cited by 115
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
Jalil, A. R., Andrechak, J. C., & Discher, D. E. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa006 · Cited by 115
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Wang, Y., Ni, H., Zhou, S., He, K., Gao, Y., Wu, W., Wu, M. H., Wu, Z., Qiu, X., Zhou, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02679-5 · Cited by 115
Cytotoxic T Lymphocytes Efficiently Recognize Human Colon Cancer Stem-Like Cells
Inoda, S., Hirohashi, Y., Torigoe, T., Morita, R., Takahashi, A., Asanuma, H., Nakatsugawa, M., Nishizawa, S., Tamura, Y., Tsuruma, T., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.004 · Cited by 115
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell–macrophage lineage
Egeler, R. M., van Halteren, A. G. S., Hogendoorn, P. C. W., Laman, J. D., & Leenen, P. J. M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00883.x · Cited by 117
Venetoclax resistance: mechanistic insights and future strategies
Ong, F., Kim, K., & Konopleva, M. Y. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.125 · Cited by 113
Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside
Jinushi, M., & Komohara, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.002 · Cited by 115
Harnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 114
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
Ågerstam, H., Karlsson, C., Hansen, N., Sandén, C., Askmyr, M., von Palffy, S., Högberg, C., Rissler, M., Wunderlich, M., Juliusson, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422749112 · Cited by 111
Notch Signaling Modulates Macrophage Polarization and Phagocytosis Through Direct Suppression of Signal Regulatory Protein α Expression
Yan, L., Zhao, J., Zheng, Q., Jiang, X., Tian, J., Liang, S.-Q., Guo, H., Qin, H., Liang, Y., & Han, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01744 · Cited by 113
CD 47‐signal regulatory protein α signaling system and its application to cancer immunotherapy
Murata, Y., Saito, Y., Kotani, T., & Matozaki, T. (2018) · Cancer Science · doi:10.1111/cas.13663 · Cited by 110
Putting the brakes on phagocytosis: “don't-eat-me” signaling in physiology and disease
Kelley, S. M., & Ravichandran, K. S. (2021) · EMBO Reports · doi:10.15252/embr.202152564 · Cited by 117
Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47
Hu, H., Cheng, R., Wang, Y., Wang, X., Wu, J., Kong, Y., Zhan, S., Zhou, Z., Zhu, H., Yu, R., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153470 · Cited by 111
Cancer stem cells and niches: challenges in immunotherapy resistance
Pan, Y., Yuan, C., Zeng, C., Sun, C., Xia, L., Wang, G., Chen, X., Zhang, B., Liu, J., & Ding, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02265-2 · Cited by 117
Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use
Liersch, R., Müller‐Tidow, C., Berdel, W. E., & Krug, U. O. (2014) · British Journal of Haematology · doi:10.1111/bjh.12750 · Cited by 118
Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies
Sáinz, B., Carron, E. C., Vallespinós, M., & Machado, H. L. (2016) · Mediators of Inflammation · doi:10.1155/2016/9012369 · Cited by 115
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu, Y., Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.12.001 · Cited by 112
The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia
Brierley, C. K., Staves, J., Roberts, C., Johnson, H., Vyas, P., Goodnough, L. T., & Murphy, M. F. (2019) · Transfusion · doi:10.1111/trf.15397 · Cited by 109
CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.140 · Cited by 108
Self-citation
The development of bispecific antibodies and their applications in tumor immune escape
Zhang, X., Yang, Y., Fan, D., & Xiong, D. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0072-7 · Cited by 112
Mechanisms of Immune Tolerance in Leukemia and Lymphoma
Curran, E. K., Godfrey, J. K., & Kline, J. P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.004 · Cited by 108
CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients
Barrera, L., Montes-Servín, E., Hernandez‐Martinez, J., García-Vicente, M. D. L. Á., Montes-Servín, E., Herrera-Martínez, M., Crispín, J. C., Borbolla-Escoboza, J. R., & Arrieta, O. G. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.173 · Cited by 108
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
Schürch, C. M., Riether, C., Matter, M. S., Tzankov, A., & Ochsenbein, A. F. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45977 · Cited by 110
Application of advances in endocytosis and membrane trafficking to drug delivery
Ju, Y., Guo, H., Edman, M. C., & Hamm‐Alvarez, S. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.026 · Cited by 110
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
Khaldoyanidi, S. K., Nagorsen, D., Stein, A. S., Ossenkoppele, G. J., & Subklewe, M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00475 · Cited by 108
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
Bouwstra, R., van Meerten, T., & Bremer, E. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.943 · Cited by 111
Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47
Huang, C., Wang, X., Wang, Y., Feng, Y., Wang, X., Chen, S., Yan, P., Liao, J., Zhang, Q., Mao, C., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00691-z · Cited by 112
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
O'Hear, C. E., Heiber, J. F., Schubert, I. A., Fey, G. H., & Geiger, T. L. (2014) · Haematologica · doi:10.3324/haematol.2014.112748 · Cited by 107

Authors: Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L.
Affiliations: Stanford Medicine (US)
Institute for Stem Cell Biology and Regenerative Medicine (US)
Stanford University (US)
Corresponding author: Majeti, Ravindra
Weissman, Irving L.
ORCID: Majeti, Ravindra
Chao, Mark P.
Alizadeh, Ash A.
Pang, Wendy W.
Jaiswal, Siddhartha
Gibbs, Kenneth D.
Weissman, Irving L.
Venue: Cell
Publisher: Elsevier BV
Published: 2009-07
Volume: 138
Issue: 2
Pages: 286-299
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2009.05.045
PMC: PMC2726837
OpenAlex: W2097126393
Cited by: 1,752
References: 47
Citations by year: 2026: 73 · 2025: 143 · 2024: 149 · 2023: 183 · 2022: 147 · 2021: 163 · 2020: 142 · 2019: 106 · 2018: 86 · 2017: 108 · 2016: 78 · 2015: 85 · 2014: 61 · 2013: 65 · 2012: 67
FWCI: 22.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1477 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (R01 CA86017, R01CA086017, T32CA009302)
National Institute of Allergy and Infectious Diseases (T32AI007290)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords: CD47, acute myeloid leukemia, leukemia stem cells, prognostic factors, anti-CD47 monoclonal antibody, phagocytosis, overall survival, engraftment, targeted therapy
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Phagocytosis, Prognosis, Receptors, Immunologic, Leukemia, Myeloid, Acute, Mice, CD47 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks